Current Therapy for Hypercholesterolemia

Blum, Conrad B.; Levy, Robert I.

doi:10.1001/jama.1989.03420240096034

Cited by 36 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lowering serum levels of LDL-cholesterol is considered to reduce the risk of coronary heart disease and atherosclerosis (4,5). Thus, FV will have therapeutic utility for the treatment of hypercholesterolemia (6).…”

Section: Introductionmentioning

confidence: 99%

Effect of fluvastatin, an inhibitor of 3-hydroxy-3-methyl glutaryl CoA reductase, on drug-metabolizing enzymes in rats

Ohtawa¹,

Masuda²,

Karasawa³

et al. 1995

European Journal of Drug Metabolism and Pharmacokinetics

View full text Add to dashboard Cite

Fluvastatin (FV), a new cholesterol-lowering agent, has been studied for its effects on hepatic microsomal drug-metabolizing enzymes in male rats. FV was orally administered in dosages of 1, 5, and 30 mg/kg/day for 7 consecutive days. 3-Hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase activities were markedly decreased at all dose levels. The amount of microsomal protein and the contents of cytochromes P450 and b5 did not change. No induction of aniline hydroxylase, aminopyrine N-demethylase, testosterone hydroxylases (15 alpha-, 7 alpha-, 6 beta-, 16 alpha-, and 16 beta-), and UDP-glucuronosyltransferase were found. On the other hand, 7-ethoxycoumarin o-deethylase activity was slightly increased and lauric acid omega-1-hydroxylase activity tended to be decreased after treatment with FV.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of fluvastatin, an inhibitor of 3-hydroxy-3-methyl glutaryl CoA reductase, on drug-metabolizing enzymes in rats

Ohtawa¹,

Masuda²,

Karasawa³

et al. 1995

European Journal of Drug Metabolism and Pharmacokinetics

View full text Add to dashboard Cite

show abstract

“…Despite the well known problems with cutaneous and gastrointestinal side‐effects, niacin has a long‐standing experience of safety and efficacy and is modest in cost. Also, niacin typically reduces low density lipoprotein cholesterol (LDL‐C) and TG while at the same time raising levels of HDL‐C 4 …”

mentioning

confidence: 99%

Treatment of Hypercholesterolemia: Comparison of Younger versus Older Patients Using Wax‐Matrix Sustained‐Release Niacin

Keenan

Bae²,

Fontaine³

et al. 1992

J American Geriatrics Society

View full text Add to dashboard Cite

show abstract

“…The goals of lipid-lowering treatment that is expected to reduce the incidence of athero sclerotic disease are a total cholesterol level < 200 mg/dl (5.17 mmol/1) and a low-densitylipoprotein (LDL) cholesterol level < 160 mg/ dl (4.14 mmol/1) or, in the presence of other coronary heart disease risk factors, an LDL level <130 mg/dl (3.36 mmol/1) [1], These goals are seldom achieved in patients with familial hypercholesterolemia (FHC) who receive dietary and single-drug treatment. Strict dietary regimens reduce the cholesterol level by approximately 10%; cholestyramine monotherapy, if tolerated, reduces it by 20-30% [2]; and 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhib itors will lower cholesterol 30-40% [3,4], If the cholesterol level at the outset is that char acteristic of heterozygous FHC.…”

mentioning

confidence: 99%

Combination Drug Therapy with HMG CoA Reductase Inhibitors and Bile Acid Sequestrants for Hypercholesterolemia

1990

Cardiology

View full text Add to dashboard Cite

Single-drug therapy is often not sufficient to lower total and low-density lipoprotein (LDL) cholesterol levels in patients with familial hypercholesterolemia to desirable or target levels. Therefore, combination drug therapy is often necessary.The most potent therapy to achieve this goal is a combination of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor, which reduces cholesterol synthesis, and a bile acid sequestrant, which indirectly depletes the intrahepatic cholesterol pool. LDL cholesterol reductions reportedly vary between 52 and 54% in short-term trials. Combining a bile acid sequestrant with nicotinic acid reduces LDL cholesterol 34-55% and with a fibrate, 12-42%. The triple-drug regimen of bile acid sequestrant, an HMG CoA reductase inhibitor, and nicotinic acid is even more effective, achieving reductions of 59-67%. All these regimens elevate high-density lipoprotein cholesterol levels concomitantly by 2-37%.

show abstract

Current Therapy for Hypercholesterolemia

Cited by 36 publications

References 29 publications

Effect of fluvastatin, an inhibitor of 3-hydroxy-3-methyl glutaryl CoA reductase, on drug-metabolizing enzymes in rats

Effect of fluvastatin, an inhibitor of 3-hydroxy-3-methyl glutaryl CoA reductase, on drug-metabolizing enzymes in rats

Treatment of Hypercholesterolemia: Comparison of Younger versus Older Patients Using Wax‐Matrix Sustained‐Release Niacin

Combination Drug Therapy with HMG CoA Reductase Inhibitors and Bile Acid Sequestrants for Hypercholesterolemia

Contact Info

Product

Resources

About